TREANDA Drug Patent Profile

Which patents cover Treanda, and when can generic versions of Treanda launch?

Treanda is a drug marketed by Cephalon and is included in one NDA. There are nine patents protecting this drug and two Paragraph IV challenges.

This drug has sixty-six patent family members in twenty-one countries.

The generic ingredient in TREANDA is bendamustine hydrochloride. There are twenty-three drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the bendamustine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Treanda

A generic version of TREANDA was approved as bendamustine hydrochloride by ACCORD HLTHCARE on December 7^th, 2022.

Summary for TREANDA

International Patents:	66
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	130
Clinical Trials:	107
Drug Prices:	Drug price information for TREANDA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TREANDA
What excipients (inactive ingredients) are in TREANDA?	TREANDA excipients list
DailyMed Link:	TREANDA at DailyMed

See drug prices for TREANDA

Recent Clinical Trials for TREANDA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Regeneron Pharmaceuticals	Phase 3
Vaishalee Kenkre	Phase 1/Phase 2
University of Wisconsin, Madison	Phase 1/Phase 2

See all TREANDA clinical trials

Pharmacology for TREANDA

Drug Class	Alkylating Drug
Mechanism of Action	Alkylating Activity

Paragraph IV (Patent) Challenges for TREANDA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TREANDA	Injection	bendamustine hydrochloride	90 mg/mL, 0.5 mL and 2 mL in single- dose vials	022249	1	2014-06-19
TREANDA	Injection	bendamustine hydrochloride	25 mg/vial and 100 mg/vial	022249	10	2013-06-04

US Patents and Regulatory Information for TREANDA

TREANDA is protected by nine US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cephalon	TREANDA	bendamustine hydrochloride	POWDER;INTRAVENOUS	022249-002	May 1, 2009	AP	RX	Yes	Yes					Y
Cephalon	TREANDA	bendamustine hydrochloride	SOLUTION;INTRAVENOUS	022249-003	Sep 13, 2013		DISCN	Yes	No					Y
Cephalon	TREANDA	bendamustine hydrochloride	POWDER;INTRAVENOUS	022249-002	May 1, 2009	AP	RX	Yes	Yes					Y
Cephalon	TREANDA	bendamustine hydrochloride	POWDER;INTRAVENOUS	022249-002	May 1, 2009	AP	RX	Yes	Yes					Y
Cephalon	TREANDA	bendamustine hydrochloride	POWDER;INTRAVENOUS	022249-001	Mar 20, 2008	AP	RX	Yes	Yes					Y

International Patents for TREANDA

When does loss-of-exclusivity occur for TREANDA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

European Patent Office

Hong Kong

Japan

Mexico

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TREANDA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	052877	COMPOSICIONES FARMACEUTICAS DE BENDAMUSTINA
Australia	2006204817	Bendamustine pharmaceutical compositions for lyophilisation
Brazil	PI0606332	composição farmacêutica de bendamustina, preparação liofilizada, forma de dosagem farmacêutica, método para obter aprovação oficial para um produto de bendamustina, processo para fabricar uma preparação liofilizada de bendamustina, solução ou dispersão de pré-liofilização de bendamustina, pó liofilizado, método para preparar uma preparação liofilizada de bendamustina, formulação para liofilização, e, uso de uma solução farmaceuticamente aceitável
Canada	2593582	COMPOSITIONS PHARMACEUTIQUES DE BENDAMUSTINE (BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS FOR LYOPHILISATION)
China	101119708	Bendamustine pharmaceutical compositions

TREANDA (bendamustine): Market dynamics and financial trajectory across geographies, pricing pressure, and patent cliff risk

Last updated: July 29, 2026

TREANDA’s commercial profile is defined by oncology-indication exposure (notably chronic lymphocytic leukemia, and other hematologic malignancies), ongoing price compression in legacy generics, and steady erosion from competitive alternatives in the US and key EU markets. The product’s revenue trajectory also reflects intensified payer controls, formulary tightening, and margin pressure from channel inventory cycles as generic bendamustine competes at lower net prices.

What are the current TREANDA market dynamics in the US and key EU markets?

Answer: TREANDA faces persistent downward pricing pressure driven by generic bendamustine competition, payer-driven site-of-care and formulary controls, and substitution economics where interchangeability and low-cost sourcing exist.

US: what drives net price compression for bendamustine products?

• Generic substitution dynamics. Bendamustine HCl is a long-established cytotoxic; once generic entrants consolidated, average selling price trajectories for branded TREANDA typically track net price compression tied to gross-to-net declines.
• Payer controls for chemotherapy. Commercial and government payers increasingly use:
  • step edits and prior authorization,
  • lowest-cost contracting,
  • bundled reimbursement pressures at infusion centers, and
  • narrow formularies in hematology/oncology pharmacy benefit management.
• Acquisition and contracting cycles. Oncology drugs often experience faster competitive share shifts during contract renewals than in other therapy areas because infusion-center procurement is highly sensitive to acquisition cost.

EU: where do market access frictions show up most?

• Tender-based pressure. Several EU markets use hospital tenders for oncology cytotoxics, where branded products lose share quickly after generic availability.
• Regulatory and supply considerations. Even with multiple suppliers, cytotoxic manufacturing constraints can create short-term supply tightness. Those episodes typically support temporary pricing stability, but long-term tenders still trend toward cost-based procurement.

How has TREANDA revenue evolved over time given generic bendamustine competition?

Answer: TREANDA revenue has followed a typical “legacy brand” trajectory: peak years driven by exclusivity and limited competition, then multi-year compression as generic bendamustine expanded and share migrated to lower-priced supply.

Financial trajectory pattern (what to expect)

• Early phase: stronger brand share and higher net pricing.
• Mid phase: generic entrants trigger gross-to-net expansion for the brand through rebates and contracting discounts.
• Late phase: brand market position becomes largely dependent on:
  • limited remaining formulary access,
  • clinician preference in specific regimens,
  • procurement relationships in oncology centers, and
  • supply reliability or product handling requirements.

Key metrics that govern the trajectory

• Unit share at infusion centers: even a stable unit count becomes less profitable as net pricing declines.
• Net-to-gross ratio: increases as competitive contracting intensifies.
• Contract concentration: a small number of large buying groups can dominate quarterly revenue volatility.

What competitive forces affect TREANDA’s market share and pricing?

Answer: Generic bendamustine supply expansion and payer procurement economics are the primary forces; regimen shifts in CLL and related hematologic indications are secondary drivers that can reduce the addressable TAM even if dosing remains consistent.

Competitive force map

• Cost competition: generic pricing sets the ceiling for brand net prices through bidding and contracting.
• Regimen competition in CLL: therapeutic alternatives beyond bendamustine-based strategies can reduce cycles per patient and shift patient flow to other classes.
• Clinical pathway changes: treatment sequencing in indolent and aggressive lymphomas can alter how often bendamustine is selected as first-line vs later-line therapy.
• Administration and patient handling: product-specific packaging and infusion protocols can matter in oncology operations, but these rarely offset the economics of generic substitution for long.

When does TREANDA face the biggest revenue risk from patent and exclusivity expiration?

Answer: The biggest branded revenue risk occurs around exclusivity and patent cliffs, followed by post-cliff discounting and market share transfer to multiple generic suppliers.

Patent and exclusivity: how the revenue risk typically materializes

For cytotoxic small molecules like bendamustine:

• Exclusivity/patent expiration enables generic entry.
• Post-approval competition compresses net prices quickly in procurement-heavy oncology settings.
• Multi-supplier fragmentation can stabilize supply but keeps prices low, limiting branded recovery.

How to translate patent timing into financial impact

• Contract cycles: branded revenue decline often lags the initial generic approvals by one or two procurement periods.
• Inventory dynamics: when contracts change, infusion centers can shift procurement within a quarter or two.
• Rebates and access: the brand may increase discounts to defend share, raising net-to-gross and lowering profitability even before volumes move.

What is TREANDA’s FDA and regulatory status and how does it affect market entry risk?

Answer: Market entry risk is governed by the ability for generic competitors to file and obtain approval pathways tied to the reference listed drug and its regulatory history.

US regulatory mechanics affecting TREANDA

• Generic approval pathway: when exclusivity ends, generic applications can seek approval that permits marketing with the reference product’s labeling.
• Orphan exclusivity and exclusivity blocks: for legacy oncology drugs, the presence or absence of block periods determines the speed of generic entry after initial protections end.
• Label changes: any post-approval safety or dosing updates can affect generic label matching and launch timing.

How do biosimilar and biologics risks compare for TREANDA?

Answer: Biosimilar risk is generally low because TREANDA is a small-molecule cytotoxic, not a biologic.

What takes the place of biosimilar competition

• Generic small-molecule competition is the relevant threat.
• New targeted therapies and cellular therapies can change CLL and lymphoma sequencing, reducing bendamustine utilization even if generics are available.

What generic entry scenarios are most likely to pressure TREANDA margins?

Answer: The highest pressure scenario is multi-supplier generic penetration paired with aggressive contracting that forces brand net pricing near acquisition cost.

Generic entry playbook (how it hits the P&L)

• First entrant: creates immediate price benchmark; brand counters with rebates.
• Second and third entrants: increase competitive intensity and accelerate share shifts; brand discounting continues but volumes fall.
• Tender normalization: hospitals align with lowest-cost suppliers for the tender cycle, reducing brand differentiation.
• Wholesale channel effects: distribution becomes dominated by low-cost product, making it difficult for the brand to regain volume.

How does TREANDA compete against other oncology drugs used in similar indications?

Answer: TREANDA’s competitive set includes other CLL/lymphoma regimens that can displace bendamustine through efficacy, toxicity profile, administration convenience, and payer coverage.

Competitive dimensions that matter to access

• Administration schedule: shorter or more convenient regimens can win within infusion-center capacity constraints.
• Tolerability: cytotoxic toxicity can drive selection of alternative agents with more manageable side-effect profiles.
• Line-of-therapy positioning: newer standards can move bendamustine from earlier lines to later lines, shrinking addressable demand.
• Payer coverage: formulary preference can be decisive when multiple clinically acceptable regimens exist.

What formulation, method-of-use, and manufacturing IP barriers exist around bendamustine for competitors?

Answer: For small molecules, the main launch barrier is typically patent coverage on drug substance and specific delivery/formulation approaches rather than complex biologic manufacturing IP.

Common IP barrier categories relevant to cytotoxics

• Composition patents: cover bendamustine formulations and specific excipients/ratios.
• Process patents: cover manufacturing steps and purification constraints.
• Method-of-use: covers specific regimens, combination therapies, dosing schedules, or patient subsets.

Financial relevance

• The practical effect for TREANDA revenue is whether generic competitors face:
  • launch delay from non-expired claims,
  • slower market penetration due to formulation switching or litigation, or
  • full-speed generic normalization with rapid net price erosion.

What TREANDA licensing or settlement dynamics typically matter for brand survival?

Answer: Licensing outcomes that permit generic marketing without carve-outs accelerate branded share loss. Settlements that delay competition can create temporary revenue support but usually cannot reverse multi-year pricing compression.

What to watch in market outcomes

• Authorized generic arrangements: can maintain “brand-labeled” distribution while driving down average realized prices.
• Bargained access: settlements sometimes trade delay for broader market permission or exclusivity-like arrangements.
• Non-monetary terms: supply obligations and label restrictions can affect how quickly pricing collapses.

Key market timeline: how the commercial story usually unfolds for TREANDA-like oncology brands

Answer: A high-level “brand lifecycle” timeline typically maps to (1) generic approvals, (2) contract renewal cycles, and (3) sustained pricing normalization.

Timeline framework (commercial impact mapping)

• Pre-generic period: brand pricing supported by exclusivity.
• First generic launch window: brand net price begins to erode as channels benchmark.
• Post-second/third entrant window: share shifts materially; rebates and discounts increase.
• Tender normalization: branded share often becomes residual and concentrated in specific facilities.

Revenue exposure: how sensitive is TREANDA to US share vs ex-US markets?

Answer: For many legacy oncology brands, US share and pricing typically dominate revenue exposure because net price compression is fastest in the US procurement cycle. Ex-US markets can act as either a partial offset (if tenders retain branded access longer) or another pressure channel (if tender cycles move quickly to generics).

Sensitivity drivers

• Bulk purchasing power: group purchasing can accelerate displacement.
• Tender cycles: quarterly or semiannual cycles can cause stepwise revenue drops.
• Regimen selection: where bendamustine remains standard, volume erosion is slower even as pricing declines.

How strong is TREANDA’s patent estate for defending market exclusivity (and what does that mean for investors)?

Answer: Brand defense strength usually diminishes once multiple generic entries exist. For small molecules, patent estates tend to fragment across claim types, and even partial claim success can only slow share transfer.

Investor implications

• If the estate is concentrated in narrow method-of-use claims, the financial effect is typically delay rather than long-term prevention.
• If composition and manufacturing claims remain broad and enforceable, generic entry and price normalization slow, extending the revenue curve.

Key takeaways

• TREANDA’s market dynamics are dominated by generic bendamustine competition, payer procurement pressure, and oncology contracting economics.
• The financial trajectory is consistent with legacy brand compression: shrinking net pricing, rising gross-to-net, and gradual share loss.
• The biggest branded revenue risk is tied to exclusivity and patent cliff timing, followed by rapid contracting changes and multi-supplier normalization.
• Biosimilar risk is not applicable in the usual sense because TREANDA is a small-molecule; the primary displacement threats come from generics and regimen shifts in CLL/lymphoma treatment.

FAQs

1. What impact do infusion center contracting and tender cycles have on TREANDA net sales?
2. How does generic bendamustine competition typically change TREANDA gross-to-net and operating margin?
3. Which CLL or lymphoma regimens most reduce bendamustine utilization after new standards emerge?
4. Do method-of-use patents meaningfully delay generic competition for bendamustine products?
5. How does supply reliability of cytotoxic products affect short-term pricing stability for TREANDA?

References (APA)

1. FDA. (n.d.). Drug approvals and databases (Orange Book and related regulatory resources). U.S. Food and Drug Administration.
2. CMS. (n.d.). Medicare reimbursement and drug pricing resources. Centers for Medicare & Medicaid Services.
3. EMA. (n.d.). EU medicines information and authorization resources. European Medicines Agency.